Revolutionising Oncology Medicine: A Precision ...

By HEOR Staff Writer

July 11, 2023

In a groundbreaking study published in Journal of Pharmaceutical Policy and Practice volume, an analysis was conducted on the R&D costs of oncology medicines. The analysis, based on data from company filings fro...
The Power of Pharmacist Interventions in Improving Glycemic Control for Diabe...
EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable
SAHPRA and partners successfully complete second cohort of Clinical Assessors...
Mystery caller study on emergency contraception in Germany!
The updated Medscheme specialised drug list for 2023 has been published
Equity in Global Health Research: Lessons from the 8Quity Tool
Prioritizing Mental Health in South African Medical Schemes: Challenges and O...
Multiple myeloma is the second most common type of blood cancer, with approxi...
HTA must consider health equity for progress
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Eval...
Increases in drug prices are of concern to worldwide health systems
HEOR Theater focusing on discussions from the ISPOR HTA Roundtable